ImmPACT Bio Granted FDA Fast Track Designation for IMPT-314 in Patients with Relapsed or Refractory Aggressive B Cell Lymphoma

ImmPACT Bio USA, Inc. announced the US FDA has granted Fast Track Designation for IMPT-314, a potential first-in-class CD19/CD20 CAR T therapy for the treatment of patients with B cell mediated malignancies.